Postoperative acute pain
Conditions
Interventions
Oliceridine analgesic group:The Oliceridine analgesia group used 10mg/10ml Oxalidine 2 tubes+80ml saline infusion pump with a loading dose of 1.6mg (8ml), followed by a patient-controlled analgesia re
Sufentanil analgesic group:The sufentanil analgesia group received two doses of 50ug/1ml sufentanil and 98ml saline solution with a loading dose of 8 µ g (8ml), followed by a patient-controlled analge
Sponsors
Wu Jieping Medical Foundation Committee
Eligibility
Sex/Gender
All
Age
55 Years to 85 Years
Inclusion criteria
Inclusion criteria: Approved by the ethics committee, all selected patients have signed informed consent forms for the study. Select patients who underwent abdominal surgery and general anesthesia at the AICU of Weifang People's Hospital from November 2024 to October 2025. Inclusion criteria: Patients with American Society of Anesthesiologists (ASA) physical condition grades I to III (I represents healthy patients, II represents mild systemic disease patients, III represents severe systemic disease patients); Patients aged between 55-85 who plan to undergo abdominal surgery and enter AICU after surgery.
Exclusion criteria
Exclusion criteria: Exclusion criteria: Patients refuse to participate in the study; Weight35kg/m2; Pregnant or lactating women; History of opioid allergy; Diagnose or suspect sleep apnea; Use of chronic opioid therapy (>15 morphine equivalent units per day for>3 days/week and>1 month within 1 year after surgery); Use any analgesic within five half lives before surgery (48 hours if unknown); Long term use of nonsteroidal anti-inflammatory drugs for the treatment of diseases (daily use for more than 2 weeks within 6 months before surgery, but if the patient uses aspirin = 325mg per day for cardiovascular disease prevention and has been stably treated for more than 30 days, it is allowed); Use drugs that may affect the analgesic effect (central alpha adrenergic drugs, antiepileptic drugs, antipsychotic drugs, antidepressants, or antipsychotic drugs), which have not been consistently administered for at least 30 days prior to surgery; Oral or parenteral administration of corticosteroids within 3 months prior to surgery; Or liver or kidney damage may occur during screening; Suffering from mental and neurological disorders, gastrointestinal obstruction, chronic obstructive pulmonary disease, or pulmonary heart disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numeric Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay;The incidence and severity of adverse events within two days after surgery;The number of compressions and actual effective dosage of analgesic pump;Intraoperative dosages of sufentanil and remifentanil;AIS;Time from discontinuation of medication to extubation; | — |
Countries
China
Contacts
Public ContactBao Lang
Weifang People's Hospital
Outcome results
None listed